Decoding the CGT Industry Growth Code: Quality, Supply Chain, and Capital Services @ CSGCT Park Tour – Guangzhou Station

Speakers

Professor Gong Chen is the Founder and Chief Scientist of NeuExcell Therapeutics, as well as an internationally renowned expert in regenerative medicine. He earned his bachelor’s degree from Fudan University and his Ph.D. in Neurobiology from the Shanghai Institute of Physiology, Chinese Academy of Sciences. He previously served as a tenured professor at Pennsylvania State University. His team pioneered the use of the neural transcription factor NeuroD1 to convert glial cells into functional neurons in situ, opening new avenues for the treatment of neurodegenerative diseases such as Alzheimer’s disease and stroke. He holds over 200 international patents. Under his leadership, NeuExcell Therapeutics entered into a $190 million collaboration with Spark Therapeutics, a Roche subsidiary, and was recognized as one of the “Top Five Promising Gene Therapy Companies in Asia.”

Earned a Ph.D. from Hokkaido University in Japan, with a focus on protein structure elucidation.

Dr. Gai is responsible for the company’s overall operations and strategic planning, playing a central role in driving corporate development and technological innovation.

As the founder and CEO of EdiGene, Dr. Gai has leveraged his extensive experience and expertise in the biotechnology sector to successfully lead the company in achieving significant advancements in gene editing technology and driving its expansion into global markets.

Co-founder and CEO of Baiji Biotech, fully responsible for core matters including the company’s global strategic layout, business operations, financing and M&A, government relations, and international cooperation.

With over 20 years of experience in multinational corporate management and the biopharmaceutical industry, has held executive positions at multiple Fortune 500 companies, possessing profound expertise in corporate operations and capital management.

Investment Director, Gangyue Capital

B.S. in Pharmacy from Peking University, Ph.D. in Chemistry from the Institute of Chemistry, Chinese Academy of Sciences, and M.Fin. from the University of International Business and Economics. Candidate for Think Tank Expert at CITIC Group & Healthcare Industry Expert at the Suzhou Branch; Director of the Healthcare Industry Group, Investment Banking Committee, CITIC Securities; licensed to practice in China, Hong Kong, and the United States. Recipient of two “New Fortune” Best Analyst awards in 2021 and nominated for a “New Fortune” award in a specific category in 2022.

Dr. Zhang Yang joined CITIC Securities in 2014. He completed the RMB 1.18 billion financing for Shanghai Allist Pharmaceutical and the USD 110 million financing for OrbusNeich. He led the IPO of Chengda Biotechnology, the first company spun off from a Chinese listed firm to list on the STAR Market (the first approved “A-share to A-share” spin-off), as well as the STAR Market IPOs for Yuekang Pharmaceutical, Yuandong Biology, Trauer Biotech, Haichuang Pharma, Jinjiang Electronics, Aerospace Taixin, and Yingli Pharmaceutical. He also managed the Beijing Stock Exchange IPO for Kangleshishi; the Hong Kong stock IPOs for Chengda Biotechnology, Hepu Medicine, CARsgen Therapeutics, Imeik, Bio-Thera Solutions, and Junshengtai Pharma; and the NASDAQ IPO for Kewei Biologics. He served as joint lead underwriter for Frontier Biotechnologies and 3SBio; handled refinancing for Kaipu Biology (the first case under the registration-based system) and Tofflon Science & Technology; advised on China Resources Pharmaceutical’s acquisition of Boya Bio-pharmaceutical; and facilitated financing for China Resources Biopharmaceutical and Lixin Pharmaceutical. Additionally, he provided financial advisory services for CARsgen Therapeutics, Xingfu Chemical, Chengyi Pharmaceutical, Cyagen Biosciences, and Shenda Endoscopy. The cumulative amount of capital raised exceeds RMB 23.2 billion.

Creator of the ZCBI (Zhongguancun Life Science Park CITIC Securities Bioeconomy IPO Index).

Former Head of Marketing, Greater China, Danaher Biotechnology Group; previously held positions including Asia-Pacific Marketing Director, Greater China Marketing Director, Consumables Sales Manager, Business Development Manager, and Product Manager at companies such as Cytiva, GE Life Sciences, PerkinElmer, and Thermo Fisher Scientific.

Ph.D. in Strategy, University of Montpellier (France); EMBA, Nankai University; M.Sc. in Biology, University of Manchester; Postgraduate studies in Finance, The University of Hong Kong; currently pursuing an M.Sc. in Psychology at Arizona State University (USA). Industry Professor at UCMT; Honorary Director of GDA. Senior Engineer in Measurement, Testing, and Instrumentation across China. Thesis Supervisor for Ph.D. in Health Management, DBA, and MBA programs at the University of Montpellier (France); Distinguished Lecturer for workshops at the Business School of The University of Hong Kong and the Business School of Nankai University; Lecturer for the Advanced Leadership Training Program in Biopharmaceuticals at Peking University Health Science Center; Guest Lecturer at Yihong Business School. Deputy Director of the MAH Special Committee under the Chinese Pharmaceutical Enterprise Management Association; Chief Researcher at the Life Sciences Enterprise Research Center of E-Drug Manager; Special Researcher at the China Biopharmaceutical Infrastructure Alliance. Planner/Host of the “ChatCGT” column.

Holding a Master’s degree in Biochemical Engineering from East China University of Science and Technology, he currently serves as the Head of Marketing for Sartorius BPS in China. He has previously held positions at Sartorius as Head of Application Services for Bioprocess Technologies, BPS Field Marketing Manager, and Manager of Single-Use Application Support.

With over 15 years of industry experience in biopharmaceutical processes, I possess a deep understanding of industry development trends and segmented market analysis. I am well-versed in biopharmaceutical process implementation strategies and advanced single-use technology application solutions. My expertise focuses on the selection, optimization, and industrial-scale upscaling of filtration processes, as well as the development of integrity testing implementation strategies and protocols based on risk assessment principles. I have participated in the selection, configuration, and design of multiple new single-use production lines in China, providing professional technical application consulting and services. I have successfully driven and participated in the localization of key application products, particularly facilitating the establishment of local production for single-use bags. Committed to advancing the biopharmaceutical industry through innovative technologies and applications, I advocate for and contribute to achieving efficient, cost-effective, and robust industrialization of bioprocesses.

Graduated with a master’s degree from the College of Life Science and Technology at Jinan University, and has subsequently worked in fields related to bioreactors and single-use products.

Extensively involved in the design and construction of upstream and downstream production lines for biopharmaceuticals at both clinical and commercial scales, with extensive experience in the field of biopharmaceutical equipment.

Guosheng Tan graduated from Nanjing University. With many years of experience in pharmaceutical and biological raw material sales and marketing, he currently serves as the Director of Key Accounts at Yeasen Biotechnology. He focuses on driving cooperation with key accounts (KA), participates in the layout of company products related to the CGT sector and the formulation of market strategies, and is well-versed in the upstream and downstream industrial chains of CGT.

Zhang Jing, Master’s degree, graduated from the School of Life Sciences and Technology at Tongji University in Shanghai, majoring in Biology.

Possesses extensive experience in the development and promotion of upstream biopharmaceutical products, with primary responsibility for managing R&D, production, and quality control related to molecular enzymes, nucleic acid extraction, and enzyme-linked immunoassay (ELISA) products. Previously participated in the applicability validation of CHO host cell protein residue detection methods at the National Institutes for Food and Drug Control (NIFDC). Currently at Yeasen Biotechnology (Shanghai) Co., Ltd., primarily responsible for product line planning, marketing strategy formulation, and product design and development for quality control solutions in the fields of gene and cell therapy, antibody drugs, and vaccines.

Event Agenda